Cygnus Capital Advisors’s Liminatus Pharma LIMN Stock Holding History

Cygnus Capital Advisors’s Portfolio LIMN Stock Details LIMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$60	Buy	+350,000	New	+$187K	0.04%	67

Other funds holding LIMN

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cygnus Capital Advisors's LIMN Position: Q1 2026 in Review

Cygnus Capital Advisors opened a new position in Liminatus Pharma (LIMN) in Q1 2026: 350,000 shares worth $60. The stake represents 0.04% of the portfolio and ranks #67 among its holdings.

15 funds tracked by Wall St. Rank hold LIMN as of Q1 2026.

Cygnus Capital Advisors held 350,000 shares of Liminatus Pharma worth $60 as of Q1 2026.
Liminatus Pharma was a new Cygnus Capital Advisors position in Q1 2026.
Liminatus Pharma made up 0.04% of Cygnus Capital Advisors's portfolio in Q1 2026, its #67 holding.
15 funds tracked by Wall St. Rank held Liminatus Pharma as of Q1 2026.

Based on Cygnus Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.